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Editorial on the Research Topic
Emerging Concepts on the NKG2D Receptor-Ligand Axis in Health and Diseases
The immune activating receptor NKG2D and its cognate ligands represent a fascinating immune
recognition system, essential to the activation of innate and adaptive effector cells. It is a
potent axis for the detection of danger recognized as MHC I-like self-molecules induced under
stress conditions or during rapid proliferation. As such, it complements the recognition of
non-self-antigens presented by classic MHC molecules, ensuring an early and efficient elimination
of threats. The strength of the NKG2D pathway relies on its capacity to: (i) activate several
immune effector cells due to the wide expression of the NKG2D receptor on lymphocytes, and
(ii) distinguish diverse types of stress via multiple ligands displaying distinct affinities and levels
of regulation.
The central dogma states that NKG2D engagement initiates or strengthens immune responses
against infected and tumor cells bymeans of cytokine and chemokine secretion and direct cytotoxic
activity. However, recently we have started to appreciate the multifaceted involvement of this
pathway in immunity and how genetic polymorphism of the NKG2D-NKG2D ligand (NKG2DL)
axis might explain the different and even contradictory outcome of NKG2D-driven responses
observed across patients in certain disease context. Still, important gaps in knowledge remain
regarding the regulation of human and mouse NKG2DL expression in space and time. The nature
of ligand (binding affinity, membrane bound vs. soluble), the amount of ligand expressed and
distribution at the membrane, and the cell types displaying ligands (tumor vs. normal tissue
vs. stroma vs. immune cells) are likely to differentially impact on disease as it progresses and
reciprocally be affected by it. Importantly, NKG2D ligand expression in healthy tissues is no
longer anecdotal and it has become clear that NKG2D can contribute to the development of
autoimmunity, highlighting the paradoxical outcome of NKG2D-NKG2DL engagement on disease
progression (protective vs. detrimental), including in cancer.
This Research Topic gathers research articles and literature reviews from leaders in the NK and
T cell biology fields highlighting recent advances on the expression and function of NKG2D and its
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ligands. Together, these 17 articles provide a timely survey of
this recognition pathway as a critical immunologic component
of health and disease to engage in further discussion and
developments in basic and translational immunology.
EXPRESSION AND REGULATION OF
NKG2D AND NKG2D LIGANDS
There are eight human ligands for NKG2D with
differential expression, affinity, and ability to be released
as soluble and exosomes-bound forms, accounting for
the difficulty to fully understand their unique and
concomitant role in complex pathologies. These ligands
are the MHC class I-related chain A and B (MICA,
MICB) proteins and the six unique long 16 (UL-
16)-binding proteins (ULBP1-6). Their counterparts
in mice are the retinoic acid early inducible gene-
1 (RAE-1α-ε), minor histocompatibility H60a-c, and
murine UL16-binding protein-like transcript 1 (MULT1)
proteins. The multiplicity of ligands warrants an efficient
immune recognition of cell extrinsic and intrinsic
danger signals.
In the last two decades, extensive knowledge uncovered
the different layers of regulation of most ligands at the
transcriptional, post-transcriptional, and post-translational
levels. Yet, the lack of a holistic characterization of the
mechanisms driving the heterogeneous expression of one or
multiple ligands in different cell types, tissues, and disease
contexts hampers their manipulation for therapeutic purposes.
Zingoni et al. provide a comprehensive overview of the
various levels of regulation of human and mouse NKG2D
ligands, focusing on the specificity and redundancy of
the molecular pathways able to simultaneously control the
expression of several NKG2D ligands in normal and pathological
settings. Further, they discuss the functional relevance of these
distinct ligands or allelic variants in their ability to modulate
NKG2D-mediated signaling consequently affecting target
cell killing.
NKG2D polymorphism has not been extensively studied
despites the rising number of allelic variants identified to
date, including over 100 known allelic variants for MICA
and MICB. Zuo et al. provide a state-of-the-art review on
the polymorphism and functional features of human NKG2D
ligands and their connections with different diseases. This
comprehensive review compares and contrasts polymorphisms
within MICA and MICB to the ULBP genes family and
discusses the evolutionary pressures that have driven NKG2DL
polymorphism. Notably, the authors discuss how viral infections
may have acted as a selective force toward differential
tissue-specific regulation of the ligands, allowing effective
anti-viral control while limiting autoimmunity. The influence
of polymorphisms on the NKG2DL expression, describing
how MICA variants dictate not only the amount of protein
expressed but also its subcellular location and shedding; the
binding affinity to NKG2D and how it impacts effector
functions are discussed. The clinical relevance of NKG2DL
polymorphisms is considered in the context of autoimmune
diseases, viral infections, cancer, and transplantation with the
goal to translate that knowledge to target the NKG2D-NKG2DL
axis for therapeutic purpose.
ULBP4 is the most polymorphic member of the ULBP
family, yet the least characterized ligand for NKG2D. Zöller
et al. discuss inconsistencies between the biochemical features
of ULBP4 in the literature and publicly available databases
and undertook to perform further biochemical and expression
analyses in three tumor cell lines: C1R, HepG32, and HeLa.
The authors confirmed several features of the mature
ULBP protein in line with the prediction by Uniprot, e.g.,
histidine 31 occupies the first position in the mature ULBP4
glycoprotein, not as previously assumed with glycine 29,
providing evidence of a recessed β1 strand of the ULBP4
α1 domain that may impact protein folding and function
compared with other ULBP molecules. They characterized
isoform 0 as a variant with a divergent carboxy-terminus
that results in a shortened mature glycoprotein. To further
study isoform 0, they generated a novel ULBP4 mAb and
compared the specificity of staining with commercially available
antibodies, raising concerns for potential artifactual staining
with the latter. Interestingly, the authors show that the cervical
carcinoma cell line HeLa does not express membrane bound
ULBP4s yet contains a large amount of ULBP4 retained
intracellularly. Finally, the authors show that the release of
soluble ULBP4 is partly due to metalloproteases and possibly
due to alternative splicing of the full-length isoform 0. These
novel interesting findings will stimulate future efforts to address
ULBP4 expression in situ and its physiological relevance in
cancer immunity.
The presence of soluble NKG2D ligands in cord blood plasma
(CBP) has been shown to be significantly higher than in adult
plasma from healthy individuals. Here, Cox et al. examined the
expression of different allelic variants for MICA and MICB in
the coding and promoter regions in CBP samples and observed
that common MICB alleles, such as MICB∗005:02, resulted in
increased concentration of soluble MICB (sMICB) with the
promoter polymorphisms P2, leading to elevated expression of
soluble MICB while the opposite was observed with promoter
polymorphisms P9. In vitro assays showed that increasing
concentration of soluble ULBP1 strongly associated with lower
percentage of IFNγ+ NK cells among stimulated PBMC and
moderately associated with CD107a+ CBP-derived NK cells.
In contrast, the concentration of neither sMICA nor sMICB
affected expression of CD107a whatever cell type studied. Yet,
when samples were stratified according to homozygous MICB
allele or promoter type, MICB∗005:02 with MICB-P2, induced
a lower % of IFN-γ+ NK cells compared with MICB∗008 with
MICB-P9 type indicating differential amount and inhibitory
potential for sMICB. While sMICB and sULBP1 were detected
in all CBP samples, sMICA was detected in only a third of
the samples. Most sMICA detected in CBP corresponded to
the Val/Val dimorphism known to be associated with a weak
binding affinity for NKG2D. Cells exposed to plasma from UCB
samples homozygous for MICA-129val showed significantly
increased percentage of IFN-γ and CD107a compared with
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those from Met/Met or Val/Met samples indicating enhanced
NK cell function. The authors propose a model that could
contribute to fetal-maternal tolerance based on the presence
of soluble NKG2D ligands in CBP. Future studies will need
to address important pending questions including identifying
the cell type(s) responsible for the presence of soluble ligands
in CBP. It will be key to also demonstrate if and how
various soluble ligand harboring different affinity (sMICB,
sULBP1 vs. sMICA) may compete for NKG2D binding on fetal
NK cells.
NKG2D IN CYTOMEGALOVIRUS
INFECTION
Cytomegalovirus (CMV) infection is a serious cause of morbidity
in immuno-compromised transplant recipients with the majority
of patients experiencing CMV re-infection or reactivation in the
absence of anti-viral prophylactic treatment. Rohn et al. address
this important topic in NK and T cell biology by determining
the association of MICA and NKG2D polymorphisms with
the clinical outcome of CMV. Both univariate and multivariate
analyses of three functional SNPs in a cohort of 181 kidney
donor-recipients’ pairs revealed that the MICA rs2596538 GG
donor genotype—known to be associated with elevated MICA
expression- is significantly less frequent in patients displaying
CMV disease during the first year after kidney transplant. Hence,
they identify the G allele status as a protective prognostic
determinant for CMV disease and the control of CMV viremia.
Along with NK cells, CMV-specific CD8+T and CD4+T cells
may be involved in controlling viral replication in an NKG2D-
dependent manner. Future studies should aim to address the
functional relevance and collaborative nature of these cell types,
as well as the influence of soluble ligands during CMV re-
infection or reactivation in transplanted patients.
With the goal to induce a strong and persistent immune
response against CMV, Hiršl et al. explored the idea of developing
a CMV vaccine vector expressing NKG2D ligands to generate
protective T cell Immunity. The present studies are built upon
previous work from the Jonjic lab where mouse CMV (MCMV)
engineered to express RAE-1 in place of immune evasion gene
m152 was proven to be highly attenuated yet retained the
ability to induce a strong CD8+ T cell response in vivo. Here,
they replaced m145 with MULT-1, a higher affinity ligand
for NKG2D than RAE-1, and showed that MULT-1-MCMV
replication in various infected tissues was attenuated in an NK
cell- and NKG2D-dependent manner. It could elicit a robust
adaptive response when transferred into immunocompromised
mice. Interestingly, the authors detected the presence of anti-
CMV antibodies in infected mice and showed that protective
immunity can be transferred to the offspring of immunized
females. Hence, the ability for such attenuated virus to induce a
durable CD8+T cell memory response and a humoral response
that can cross the placental barrier are critical features for its
use as a vector vaccine. Safety concerns require further testing
addressing whether attenuated virus can persist in the host
and potentially be reactivated in immune-compromised patients,
such as transplant recipients.
NKG2D-NKG2D LIGANDS IN
INFLAMMATION AND AUTOIMMUNITY
Various sources of stress can induce or upregulate NKG2D
ligands in healthy tissues, including immune cells, in the context
of inflammation. Four complementary review articles address an
emerging topic in the function of NKG2D-NKG2DL interactions
as a regulatory axis of immune responses broadening our views
on the potential mechanisms accounting for the conflicting role
for NKG2D reported in disease settings.
Trembath and Markiewicz review the growing literature
regarding NKG2D ligand expression on healthy immune
cells, including on activated T cells, B cells, NK cells, and
myeloid cells. The discussion encompasses studies reporting
opposing effects of ligand induction on immune cells, either
killing, suppressing, and/or stimulating the proliferation and
functional activities of NKG2D-expressing cells, with evidence
of reciprocal effects during cell-cell interactions. They discuss
how the “immunological multi-purposing” of NKG2D-NKG2DL
interactions can fine-tune immune responses toward different
biological outcome in immune homeostasis, tumor immunity,
and autoimmune diseases. More recently, the authors further
reported the constitutive expression of ULBP-4 on healthy
monocytes and resulting effect in downregulating NKG2D
expression on NK cells (1).
Wensveen et al. further discuss the role of NKG2D in
controlling the activation thresholds of T cells, NK cells, and
B cells. They examine evidence supporting that depending
on the intensity and duration of ligand engagement, NKG2D
can mediate both stimulatory and inhibitory signals impacting
on NK cell development and education. The authors further
discuss the anergy in T cells and NK cells induced by chronic
NKG2D stimulation and how it can be overcome in a sufficiently
inflammatory environment. Finally, they discuss unexpected
findings by their group demonstrating that the lack of NKG2D
alters mouse B1a cell development at an early pro-B progenitors
and reduce the anti-microbial activity of this subset, which are
mainly present in the peritoneal and pleural cavities of mice.
Further studies are required to support the hypothetical existence
of NKG2D signaling in an early progenitor common to NK cells
and B cells and consequent impact on gene expression relevant to
lineage commitment at later stages of B cell development.
Stojanovic et al. provide an extensive review on NKG2D
ligand expression on immune cells with a particular focus on
myeloid cells, discussing evidence of NK cell crosstalk with
dendritic cells and macrophages. The authors examine the data
generated from different types of infectious agents including
bacteria, viruses, and parasites that cause NKG2DL expression
in myeloid cells, likely through TLR signaling. They highlight
several in vitro studies reporting that other factors produced
by stromal, parenchymal, and immune cells in response to
infection upregulate NKG2D and its ligands, contributing to a
crosstalk between myeloid cells and NK cells. Besides infections,
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the authors also discuss evidence for NKG2DL expression on
myeloid cells infiltrating tumors and inflamed normal tissues
under autoimmune attack from several clinical studies, as well
as in experimental models. The nature of the NKG2DL that
functionally impact an NKG2D-mediated crosstalk of myeloid
cells and NKG2D+ lymphocytes and its outcome in vivo remains
nonetheless understudied. Whether ILC1 and ILC3 via NKG2D
also display the ability to communicate with myeloid cells under
cellular stress is not known.
Besides immune cells, ligands for NKG2D are detected in
healthy tissues under stress. Babic and Romagnani compare
and contrast the literature on the role of the NKG2D-NKG2DL
pathway in chronic inflammation and autoimmunity, discussing
Type 1 diabetes, multiple sclerosis, Experimental Autoimmune
Encephalomyelitis (EAE), Rheumatoid Arthritis (RA), celiac and
Inflammatory Bowel diseases (IBD). They underline the presence
of IL-15 as a common feature in most of these pathologies
in priming CD4+T cells and CD8+T cells into cytotoxic cells
and in driving the upregulation of NKG2D on those cells, as
well as increasing NKG2DL expression on epithelial cells. Of
importance, they discuss the enrichment of IL-17-producing cells
among NKG2D+CD4+ T cells when compared to NKG2D−
CD4+ T cells in patients with Crohn’s disease and in a model
of colitis. With regards to intestinal inflammation, Hosomi et
al. discuss novel findings from their group that uncovered the
implication of endoplasmic reticulum (ER) stress as a novel
mechanism for selective expression of the mouse NKG2D ligand
MULT-1 on epithelial cells. Whether this is also the case
in other autoimmune disease is not known, yet Babic and
Romagnani highlight that the expression of MULT-1, along
with RAE-1, in activated mouse oligodendrocytes led to their
susceptibility to killing by activated CD4+ T cells enriched
for the expression of NKG2D. Finally, the authors highlight
that these important considerations led to the development
of strategies aiming to block NKG2D-mediated activation to
effectively reduce pathogenesis, as tested in animal models of RA,
EAE, and IBD and currently in phase 2 clinical trials in patients
with active Crohn’s disease.
Similar to the gut, the liver is a tolerogenic organ that harbors
a large amount of innate lymphoid cells and under constant
exposure to pathogens. One particular feature of the liver is
the elevated presence of invariant Natural Killer T cells (iNKT),
which constitute the main immune cell type residing in this
tissue in mice. On this topic, Dulaimi et al. demonstrated the
contribution of NKG2D on iNKT cells in liver inflammation.
They employ a model of Con-A-induced hepatitis in NKG2D
wild-type (WT) vs. deficient (knockout, KO) mice to assess the
relevance of the NKG2D-NKG2DL pathway on iNKT cells. The
authors showed an upregulation of RAE-1 on hepatocytes upon
Con-A treatment associated with an increased production of
IFNγ, TNFα, and IL-4 in liver iNKT cells of NKG2D-WT mice
compared to the KO group. One key finding is that antibody-
mediated NKG2D blockade ameliorates disease by reducing liver
injury and increasing mouse survival, which correlated with
reduced cytokine production and FASL expression by iNKT
cells. Increased survival due to NKG2D blockade was not to the
level comparable to CD1d-deficient mice, however, suggesting
additional pathway(s) by which iNKT cells drive liver damage in
this model. An added value of this work is the characterization
of thymic and peripheral iNKT cells in NKG2D-deficient mice
showing that they are phenotypically and functionally similar
to wildtype mice. The literature on NKG2D in iNKT cells is
scarce (2), these valuable studies clearly demonstrate the impact
of NKG2D in NKT cell activation upon liver inflammation. Yet,
the actual contribution of NKG2D on iNKT cells as opposed to
NK cells and other T cell subsets in this model remains to be
determined. Notably, these data further probe the deleterious
effect driven by NKG2D in inflammation, feeding the model
that NKG2D-mediated liver damage could contribute to tumor
development as discuss by Sheppard et al. in the next section.
NKG2D IN CANCER IMMUNITY
While the NKG2D-NKG2DL axis is recognized as an attractive
target for immunotherapy against cancer and inflammatory
disorders—more information is needed to optimally design
and tailor strategies that either boost or block this peculiar
pathway. Hosomi et al. review the mechanisms involved in the
upregulation of NKG2DL expression in cells upon genotoxic
stress. These include activation of the DNA damage pathway
through the ATM or ATR protein kinases and through the
stimulator of interferon genes (STING)-dependent pathway
upon accumulation of cytosolic DNA. Less studied is the
role of the carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1) in tumor immunity. The authors
discuss their recent findings along other groups’ studies on the
mechanisms that suppress NKG2D-NKG2DL-mediated killing
of cancer cells. On tumor cells, CEACAM1 was shown to
prevent NKG2D ligand cell surface expression via intracellular
retention as an incompletely glycosylated protein. On NK
cells, co-engagement of NKG2D and CEACAM1 suppresses
NKG2D-mediated signaling in a SHP1-dependentmanner, hence
reducing NK cell cytotoxicity against CEACAM1-expressing
tumor cells. These data evidence the impact of CEACAM1 as a
negative regulator of NKG2D ligands on cancer cells.
The normal liver contains a large population of resident
lymphocytes largely enriched in NK cells, yet it is the site
of a number of ineffectively controlled chronic infections, of
primary hepatocellular carcinoma (HCC), and metastasis from
colorectal cancer (CRC). Easom et al. studied NK cells in HCC
and secondary liver tumors arising from CRC metastasis and
evidenced surprisingly high frequencies of NK cells infiltrating
tumors—a large majority of which displaying a liver resident
phenotype (CXCR6+CD69+). Intratumor NK cells displayed
fairly high levels of cell surface NKG2D, albeit lower compared
to NK cells located in healthy adjacent tissues. It would be very
interesting to assess whether the presence and amount of NK
cell infiltrating liver tumors correlates with disease prognosis
in HCC and metastatic CRC patients. Further, the authors
compared the level of granzyme B (GzB) expression between
healthy peripheral NK, intrahepatic NK cells [including liver
resident (lr) NK and non-lrNK cells] and tumor-infiltrating NK
cells. They show a heterogeneous expression of GzBhi and GzBlow
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expressing cells in intrahepatic and tumor-infiltrating NK cells
which contrasted with the homogeneous GzBhi level detected
in peripheral NK cells. The percentage of IFN-γ-producing NK
cells was not significantly different in tumor vs. healthy liver, yet
significantly lower than in circulating NK cells. Further studies
will be needed to directly link the reduced NK cell functionality
with NKG2D and NKG2DL expression in HCC patients. The
authors also performed overnight coculture experiments of
healthy intrahepatic NK cells with a MICA+ HCC-derived cell
line and showed the ability of the HCC cell line to downregulate
NKG2D and reduce NK cell activation. This effect was cell-cell
contact dependent and NK cell activation could be restored by
exposure to IL-15. Future work employing advanced cytometry
to assess intertumoral NK cell functional heterogeneity (3) and
autologous tumor cells in functional assays will be key, along with
developing ways to use IL-15 to potentiate NKG2D-mediated
response in situ with limited toxicity toward healthy hepatocytes.
The persistence of chronic inflammation is well-established as
a contributing factor for tumor development, especially in the
liver. The role of NKG2D-NKG2DL in this process is currently
understudied, relying on a few clinical and experimental evidence
and conflicting with its canonical function in tumor suppression.
Sheppard et al. discuss the literature regarding the prognostic
value for NKG2D ligands in various cancer types as well as
experimental evidence supporting a tumor-promoting effect of
NKG2D and CD8+T cells in models of liver injury and cancer.
A role for NK cells in HCC development is supported by
recent evidence that the accumulation of CD49a+ NK cells
in liver tumors associates with tumor progression and poor
clinical outcome (4). Sheppard et al. discussion stems from
their recent finding that NKG2D promotes rather than delays
tumor progression in a long-term model of chemically-induced
liver cancer (5). These studies showed that HCC progressed
more rapidly in NKG2D-WT than NKG2D-KO mice leading
to increased tumor burden and tumor grade in a tissue that
expresses elevated levels of membrane-bound NKG2DL. The
authors propose that at early stages of tumor development, the
expression of NKG2D ligands on precancerous lesions facilitate
tumor clearance, however, over time, chronic activation of
NKG2D+ effector cells residing in the healthy liver combined
with a partially or fully impaired NKG2D-dependent tumor
rejection within the tumor bed could favor tumor progression.
They postulate that in settings of chronic inflammation, NKG2D
sustains a feedback loop of tissue injury and repair in the healthy
tissue adjacent to the tumor which exacerbates the formation
of inflammatory niches favorable for neotumor development.
This hypothesis awaits to be supported by further demonstration
in different models of cancer and by the identification of the
cell type(s) contributing to the dual function of NKG2D. These
findings stimulate further discussion and encourage careful
considerations regarding the need to stratify patients that may
benefit from NKG2D-based therapies.
Beyond NK cells and CD8+T cells, the NKG2D-NKG2DL
system is highly relevant to γδT cell-based therapy. Bhat et al.
examined the effect of six pharmacological inhibitors of the
epigenetic modifier histone deacetylases on the expression and
shedding of several NKG2D ligands in a pancreatic and a prostate
carcinoma cell line. Exposure to Valproic acid (VPA) significantly
increased the cell surface expression of MICA, MICB, and
ULBP2, but not ULBP1, and their release as soluble forms,
highlighting discrepancy with data obtained in other cancer
types. Decreased NKG2D expression at the protein and RNA
levels were observed in activated Vδ2 T cells, but not PBMCwhen
treated with VPA and co-cultured with tumor cell lines, albeit
this did not affect their capacity to degranulate. The authors
also established a flow cytometry-based method to distinguish
high vs. low levels of histone acetylation (H3K9c) associated with
changes in the relative distribution of Vδ2 T cell subpopulations
when treated with VPA. While shedding further light on the
epigenetic regulation of NKG2D and its ligands in γδ T cells
and tumor cells, respectively, the biological significance of the
findings remains to be demonstrated using fresh tumor tissues
from prostate and pancreatic cancer patients to appreciate the
implications in forecasting VPA treatment in combination with
γδ T cell-based therapy.
With immunotherapy rapidly expanding as a novel
option in the treatment landscape of several cancer types,
two comprehensive reviews discuss the rationale for the
development of immune-based therapies exploiting the
NKG2D-NKG2DL axis. Frazao et al. review clinical studies
that describe the role of the NKG2D-NKG2DL axis in cancer
immunosurveillance indicating how NKG2D and NKG2D
ligand polymorphisms affect cancer development and the
patient response to chemotherapy. The authors review clinical
studies reporting that low NK cell numbers within tumors
associate with bad prognosis and that the expression profile
of NK cell receptors strongly influence prognosis and disease
outcome. Interestingly, they point out the exception of patients
with chronic myeloid leukemia (CML) for whom NK cell
counts are a significant predictive parameter for relapse after
imatinib discontinuation. They further discuss the potential of
Chimeric Antigen Receptor (CAR)-NK cells in complement or
alternative to CAR-t cells, focusing on the benefits of employing
NKG2D-CAR, an approach currently under trial.
Schmiedel and Mandelboim review focuses on the various
mechanisms of NKG2D ligand regulation and how these
can impact tumor evasion. The authors also discuss current
approaches that target NKG2D-NKG2DL expression for
cancer immunotherapy including approaches that directly
or indirectly interfere with the release of soluble ligands
in advanced cancer and those that aim to boost anti-
tumor responses to overcome the immunosuppressive
tumor milieu.
CONCLUSIONS
Overall, these articles illustrate key findings on the expression
and function of the NKG2D-NKG2DL axis and highlight current
challenges in the field. Outstanding fundamental questions
remain regarding the role of NKG2D in ILCs, how chronic
NKG2D signaling may affect NK and T cell metabolic status
potentially leading to a stage of “exhaustion,” and how NKG2DL
might play a role in cell recruitment to inflamed tissues. Further
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work is also needed to generate a holistic view on the evolution of
NKG2DL expression with disease stepwise progression over time
and their prognostic and/or predictive value in cancer patients.
Several approaches are underway to enhance NKG2D-
mediated tumor recognition in situ and upon adoptive transfer
of NK cells or T cells to treat cancer patients. Concomitant
with blocking inhibitory checkpoints and increasing NK cell
longevity, these approaches hold great promise for an effective
targeting of solid tumors with no tumor-associated antigens
identified. The three main challenges yet to be overcome are
how to deal with low level of ligands on advanced cancer
cells and cancer stem cells (6), and how to favor migration
of adoptively transferred cells to the tumor microenvironment
rather than residing in the healthy tissues, hence limiting toxicity
and autoimmunity.
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